Date: 2012-01-10
Type of information: Licensing agreement
Compound: immunohistochemistry (IHC) companion diagnostic test for ALK gene rearrangements
Company: Ventana Medical Systems (USA - a member of Roche Group - Switzerland) Pfizer (USA - NY) Cell Signaling Technology (USA)
Therapeutic area: Diagnostic - Cancer - Oncology
Type agreement: collaboration
licensing
Action mechanism:
Disease: non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma receptor tyrosinekinase (ALK) gene rearrangements who may benefit from Pfizer\'s XALKORI ® (crizotinib)
Details: Ventana Medical Systems, a member of the Roche Group, has entered into a collaboration agreement with Pfizer Inc. and license agreement with Cell Signaling Technology (CST) to develop the first fully automated and standardized immunohistochemistry (IHC) companion diagnostic test for ALK gene rearrangements. Ventana will develop the test which is intended to identify non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma receptor tyrosinekinase (ALK) gene rearrangements who may benefit from Pfizer's Xalkori® (crizotinib), approved in the US in August of 2011.
The test will measure the associated protein product when an ALK gene rearrangement is present. Under the terms of the agreements with Pfizer Inc. and CST, the Ventana ALK IHC diagnostic test will be based on CST's D5F3 antibody and Ventana OptiView DAB detection, for performance on Ventan automated platforms.
Financial terms:
Latest news: